临床和实验医学杂志2024，Vol.23Issue(18) ：1946-1950.DOI:10.3969/j.issn.1671-4695.2024.18.012

贝伐珠单抗联合化疗治疗老年晚期结直肠癌患者的疗效及对肿瘤标志物和生存期的影响

Efficacy of bevacizumab combined with chemotherapy in the treatment of elderly patients with advanced colorectal cancer and its impact on tumor markers and survival condition

李菲菲 纪业男 姜玲 张平英
临床和实验医学杂志2024，Vol.23Issue(18) ：1946-1950.DOI:10.3969/j.issn.1671-4695.2024.18.012
✕
  • NETL
  • NSTL
  • 万方数据

贝伐珠单抗联合化疗治疗老年晚期结直肠癌患者的疗效及对肿瘤标志物和生存期的影响

Efficacy of bevacizumab combined with chemotherapy in the treatment of elderly patients with advanced colorectal cancer and its impact on tumor markers and survival condition

李菲菲 1纪业男 1姜玲 2张平英3
扫码查看

作者信息

  • 1. 康复大学青岛中心医院(青岛市中心医院)结直肠肛门外科 山东 青岛 266042
  • 2. 康复大学青岛中心医院(青岛市中心医院)神经外科 山东 青岛 266042
  • 3. 青岛大学附属青岛市海慈医院(青岛市中医医院)门诊部 山东 青岛 266033
  • 折叠

摘要

目的 探究贝伐珠单抗联合化疗治疗老年晚期结直肠癌(CRC)患者的疗效及对肿瘤标志物和生存期的影响.方法 将2020年2月至2022年2月康复大学青岛中心医院(青岛市中心医院)和青岛大学附属青岛市海慈医院(青岛市中医医院)收治的80例老年晚期CRC患者纳入本次回顾性研究,根据治疗方式的不同分为观察组(n=38)和对照组(n=42),对照组患者接受FOLFOX化疗,观察组患者接受奥拉帕布联合贝伐单抗治疗.比较两组的近期疗效,治疗前、治疗2个月后的血清肿瘤标志物[人附睾蛋白4(HE4)、癌抗原(CA)125和CA199]水平及Karnofsky评分,不良反应发生率和干预12个月后的无进展生存期(PFS)率和总生存期(OS)率.结果 观察组的客观缓解率(ORR)为84.21％,显著高于对照组(64.29％),差异有统计学意义(P＜0.05);两组的疾病控制率(DCR)比较(92.11％vs.83.33％),差异无统计学意义(P＞0.05).观察组治疗2个月后的血清HE4、CA125和CA199水平分别为(122.30±20.12)pmol/L、(35.91±5.11)U/mL、(55.45±8.34)U/mL,均显著低于对照组[(185.06±28.23)pmol/L、(59.07±6.02)ng/mL、(83.77±9.08)U/mL],差异均有统计学意义(P＜0.05).观察组治疗2个月后的Karnofsky评分为(79.05±8.92)分,显著高于对照组[(73.14±10.11)分],差异有统计学意义(P＜0.05).观察组总不良反应发生率为7.89％,显著低于对照组(26.19％),差异有统计学意义(P＜0.05).两组治疗12个月的PFS率比较,差异无统计学意义(P＞0.05);观察组治疗12个月的OS率为84.21％,显著高于对照组(59.52％),差异有统计学意义(P＜0.05).结论 贝伐珠单抗联合化疗治疗老年晚期CRC有较好的临床疗效,可延缓疾病进展,降低血清肿瘤标志物水平,改善患者生存治疗和生存状况,且安全性较高.

Abstract

Objective To investigate the efficacy of bevacizumab combined with chemotherapy in the treatment of elderly patients with ad-vanced colorectal cancer(CRC)and its impact on tumor markers and survival condition.Methods Eighty elderly patients with advanced CRC ad-mitted to Qingdao Central Hospital,University of Health and Rehabilitation Sciences(Qingdao Central Hospital)and Qingdao Haici Hospital Affil-iated to Qingdao University(Qingdao Hospital of Traditional Chinese Medicine)from February 2020 to February 2022 were included in this retro-spective study and were divided into the observation group(n=38)and the control group(n=42)according to different treatment methods.The control group received FOLFOX chemotherapy,and the observation group received bevacizumab combination with olaparib treatment.The short-term efficacy,the levels of serum tumor markers[human epididymis protein 4(HE4),cancer antigen(CA)125,and CA199],Karnofsky score before and after 2 months of treatment,incidence of adverse reactions,progression free survival(PFS)rate,and overall survival(OS)rate after 12 months of intervention of the two groups were compared.Results The objective response rate(ORR)of the observation group was 84.21％,which was dramatically higher than that of the control group(64.29％),the difference was statistically significant(P＜0.05),but there was no statistically significant difference in disease control rate(DCR)(92.11％vs.83.33％)between the two groups(P＞0.05).The serum tumor markers levels of HE4,CA125 and CA199 in the observation group after 2 months of treatment were(122.30±20.12)pmol/L,(35.91±5.11)ng/mL and(55.45±8.34)U/mL,respectively,which were significantly lower than those in the control group[(185.06±28.23)pmol/L,(59.07±6.02)U/mL,(83.77±9.08)U/mL],the differences were statistically significant(P＜0.05).The Karnofsky score in the observation group was(79.05±8.92)points,which was significantly higher than that in the control group[(73.14±10.11)points],and the difference was statistically significant(P＜0.05).The total incidence of adverse reactions in the observation group was 7.89％,which was sig-nificantly lower than that in the control group(26.19％),and the difference was statistically significant(P＜0.05).There was no statistically significant difference in the 12-month PFS rate between the two groups(P＞0.05);the 12-month OS rate in the observation group was 84.21％,which was significantly higher than that in the control group(59.52％),and the difference was statistically significant(P＜0.05).Conclusion Bevacizumab combination with chemotherapy has good clinical efficacy in the treatment of elderly patients with advanced CRC.It can delay dis-ease progression,reduce serum tumor markers,improve patient survival quality and survival status,and has a high safety profile.

关键词

结直肠肿瘤/老年人/贝伐珠单抗/化疗/肿瘤标志物/生存

Key words

Colorectal neoplasms/Aged/Bevacizumab/Chemotherapy/Tumor markers/Survival

引用本文复制引用

基金项目

山东省医药卫生科技发展计划项目(2020WS00362)

出版年

2024
临床和实验医学杂志
首都医科大学附属北京友谊医院

临床和实验医学杂志

CSTPCD
影响因子：1.504
ISSN：1671-4695
段落导航相关论文